Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TSX VENTURE EXCHANGE  >  Acasti Pharma Inc    ACST   CA00430K4028

ACASTI PHARMA INC (ACST)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/22 05:39:59 pm
1.43 CAD   +2.88%
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensus 
Quotes 5-day view   Delayed Quote. Delayed Tsx Venture Exchange
01/16/2019 01/17/2019 01/18/2019 01/21/2019 01/22/2019 Date
1.43(c) 1.45(c) 1.48(c) 1.39(c) 1.43 Last
64 804 44 955 56 260 29 643 16 772 Volume
-1.38% +1.40% +2.07% -6.08% +2.88% Change
More quotes
Financials (CAD)
Sales 2019 -
EBIT 2019 -32,4 M
Net income 2019 -
Debt 2019 -
Yield 2019 -
Sales 2020 0,85 M
EBIT 2020 -21,9 M
Net income 2020 -
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 0
Capi. / Sales2020 136x
Capitalization 116 M
More Financials
Company
Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in... 
Sector
Pharmaceuticals
Calendar
07/22Earnings Release
More about the company
Latest news on ACASTI PHARMA INC
01/09Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents b..
GL
2018Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Sev..
GL
2018Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials ..
GL
2018Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call
GL
2018Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering..
GL
2018ACASTI PHARMA : IIROC Trading Resumption - ACST
AQ
2018ACASTI PHARMA : IIROC Trading Halt - ACST
AQ
2018Acasti Pharma Announces Pricing of $16.6 Million Underwritten Public Offering..
GL
2018Acasti Pharma Provides Clinical and Market Update
GL
2018Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock O..
GL
More news
Sector news : Pharmaceuticals - NEC
05:14pJOHNSON & JOHNSON : J&J, U.S. states settle hip implant claims for $120 million
RE
01:36pJOHNSON & JOHNSON : Expects Sales Growth to Slow -- Update
DJ
01:20pJOHNSON & JOHNSON : to Pay $120 Million to Settle Multi-State Hip Implant Claims
DJ
01:08pJOHNSON & JOHNSON : 2019 revenue forecast misses expectations
RE
09:12aGLAXOSMITHKLINE : GSK completes acquisition of -2-
DJ
More sector news : Pharmaceuticals - NEC
Chart ACASTI PHARMA INC
Duration : Period :
Acasti Pharma Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Average target price 5,60  CAD
Spread / Average Target 278%
Managers
NameTitle
Janelle D'Alvise President, Chief Executive Officer & Director
Roderick N. Carter Executive Chairman
Pierre Lemieux Chief Operating & Scientific Officer
Jean-Francois Boily Vice President-Finance
Jean-Marie Canan Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ACASTI PHARMA INC21.93%87
JOHNSON & JOHNSON1.27%350 508
PFIZER-2.57%246 674
NOVARTIS5.09%227 840
ROCHE HOLDING LTD.5.96%223 053
MERCK AND COMPANY-0.71%197 291